An oral caspase inhibitor as monotherapy or with antibiotics eradicates MRSA skin infections in mice

Abstract

AbstractStaphylococcus aureus is the leading cause of skin and soft tissue infections. With the emergence of antibiotic‐resistant bacteria, there is an unmet clinical need to develop immune‐based therapies to treat skin infections. Previously, we have shown pan‐caspase inhibition as a potential host‐directed immunotherapy against community‐acquired methicillin‐resistant S aureus (CA‐MRSA) and other bacterial skin infections. Here, we evaluated the role of irreversible pan‐caspase inhibitor emricasan as a monotherapy and an adjunctive with a standard‐of‐care antibiotic, doxycycline, as potential host‐directed immunotherapies against S. aureus skin infections in vivo. We used the established CA‐MRSA strain USA300 on the dorsum of WT C57BL/6J mice and monitored lesion size and bacterial burden noninvasively, and longitudinally over 14 days with in vivo bioluminescence imaging (BLI). Mice in four groups placebo (0.5% carboxymethyl cellulose [CMC] solution), placebo plus doxycycline (100 mg/kg), emricasan (40 mg/kg) plus doxycycline, and emricasan only were treated orally twice daily by oral gavage for 7 days, starting at 4 h after injection of S aureus. When compared with placebo, all three groups, placebo plus doxycycline, emricasan plus doxycycline, and emricasan treated group, exhibited biological effect, with reduction of both the lesion size (*p = .0277, ****p < .0001, ****p < .0001, respectively) and bacterial burden (***p = .003, ****p < .0001, ****p < .0001, respectively). Importantly, the efficacy of emricasan against S. aureus was not due to direct antibacterial activity. Collectively, pan‐caspase inhibitor emricasan and emricasan plus doxycycline reduced both the lesion size and bacterial burden in vivo, and emricasan is a potential host‐directed immunotherapy against MRSA skin infections in a preclinical mouse model.